The Zorbium® label tells veterinary staff and cat owners that the application site dries within 30 minutes and that contact should be avoided during that window. This figure appears on the label, in clinic discharge instructions, and in veterinary literature. It is the foundation of the product’s user safety profile.
It is based on a study that did not use buprenorphine.
Finding #1: The Drying Time Study Used the Carrier — Not the Drug
The Freedom of Information (FOI) Summary for NADA 141-547 is a public document on FDA’s Animal Drugs database. It summarizes what Elanco submitted to obtain FDA approval. Section V covers User Safety. Under “Drying Time,” it describes the study behind the 30-minute claim:
“A study was conducted in 20 cats randomized to 1 of 5 treatment groups (4 cats per group)… All cats received a single 1.2 mL application of vehicle transdermal solution to the dorsal cervical region.”
The FOI Summary defines the vehicle control as “the topical solution without buprenorphine (vehicle control of 50 mg/mL padimate O in ethanol).”
The conclusion:
“vehicle transdermal solution dose volumes of 1.2 mL or less applied to the dorsal cervical region of cats dried completely within 30 minutes.”
FDA’s 30-minute drying-time study used vehicle transdermal solution without buprenorphine. It does not directly establish that the finished drug product containing buprenorphine is free of transferable residual drug after 30 minutes.
Finding #2: Elanco’s Own Data Shows Buprenorphine Is Still Transferable for Days
The same FOI Summary contains a separate study — this one using the actual buprenorphine-containing formulation. It found:
- Buprenorphine was still wipeable from the application site at 2 hours, 24 hours, and 96 hours post-application
- The estimated residual buprenorphine half-life: 84.3 hours
96 hours is the full labeled duration of the drug. Buprenorphine was transferable at every measurement point across the entire window the product is marketed as active.
“Dry to touch” and “free of transferable residual drug” are not the same thing. Both statements are in Elanco’s own FDA submission. Only one appears on the label.
Finding #3: An Independent Published Study Confirms Oiliness Beyond 30 Minutes
A 2023 study in the Journal of the American Association for Laboratory Animal Science (Vol. 62, No. 4, July 2023, pp. 349–354) tested Zorbium® in mice using the actual drug. The authors reported:
“The fur was still slightly oily when mice were returned to group housing and did not appear to be dry until the 24-hour time point… Oral consumption of the product was not entirely restricted nor assessed.”
The 30-minute manufacturer guidance was applied. The fur was still oily. Oral ingestion via grooming was not measured.
Finding #4: A 2026 Research Study Still Used the 30-Minute Guidance
A February 2026 publication from Colorado State University (Kozlov et al.) using Zorbium® in guinea pigs applied the same 30-minute manufacturer drying guidance — without addressing or citing the 2023 findings. The unvalidated claim is still being used as a basis for study design four years after approval.
What the Evidence Shows Together
| Source | What It Found |
|---|---|
| FDA FOI Summary, NADA 141-547 — Drying Time Study | Vehicle only tested. No buprenorphine in solution. |
| FDA FOI Summary, NADA 141-547 — Residual Drug Study | Buprenorphine wipeable at 2, 24, and 96 hrs. Half-life 84.3 hrs. |
| JAALAS 2023 (mouse study, actual drug) | Fur still oily at 30 min. Not dry until 24 hours. Grooming ingestion not assessed. |
| CSU 2026 (guinea pig study) | Still used 30-minute manufacturer guidance uncorrected. |
| Zorbium® label (current) | States: dries within 30 minutes. |
Why This Matters for Cat Owners and Veterinary Staff
If the application site retains transferable buprenorphine beyond 30 minutes — as both Elanco’s own residual drug data and the 2023 JAALAS study indicate — then:
- Cats may ingest drug through self-grooming after the labeled “safe” window
- Multi-cat households where animals groom each other face unquantified secondary exposure risk
- Veterinary staff and owners may handle treated cats believing the site is safe
- Children in the household may be exposed beyond what the label discloses
The FDA adverse event data analyzed at zorbium.com includes reports consistent with these secondary exposure scenarios.
These Are Public Documents
Every source cited on this page is publicly available:
- FDA FOI Summary, NADA 141-547 — animaldrugsatfda.fda.gov
- JAALAS, Vol. 62, No. 4, July 2023, pp. 349–354 — published peer-reviewed research
- Zorbium® label — DailyMed, nlm.nih.gov
Nobody had to file a FOIA request for this. Nobody had to obtain internal documents. The methodology was in the approval summary the entire time.
This analysis was conducted using primary source documents obtained directly from FDA’s public database, reviewed with the assistance of AI systems (Claude and ChatGPT), and independently verified by a chemist.